Free Newsletter
VC: Cylene leads with $44M round
Cylene leads with $44M round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Cylene Pharmaceuticals
|
$44M
|
HBM BioVentures and Lilly Ventures |
The round provides funds for the clinical advancement of small molecule cancer therapies. |
|
4-Antibody
|
$18.5M
|
Advent Venture Partners |
The developer plans to use the money advance new antibodies. |
|
Claros Diagnostics
|
$7.8M
|
Oxford Bioscience Partners |
Much of the money earmarked for the development of its handheld diagnostic testing system. |
|
EyeGate Pharma
|
$2M
|
Nexus Group |
EyeGate is exploring the use of iontophoresis technology to deliver therapeutics for ocular indications. |
Be the first to comment
More stories about Venture Capital molecules antibodies Oxford Bioscience Partners HBM Bioventures cancer therapies
